Rosiglitazone,but not glimepiride,improves myocardial diastolic function in association with reduction in oxidative stress in type 2 diabetic patients without overt heart disease

Abstract

The effects of thiazolidinediones on cardiac function are controversial in humans with type 2 diabetes (T2DM) and in animals. Given the high prevalence and prognostic relevance of diastolic myocardial dysfunction in T2DM, we tested the hypothesis that by reducing oxidative stress rosiglitazone, but not glimepiride, may improve diastolic function.

This randomised cross-over study investigated 12 met-formin-treated T2DM patients without cardiovascular disease before and after 16 weeks of additional therapy with rosiglitazone (8 mg daily) or glimepiride (3 mg daily). Systolic and diastolic myocardial velocity (E’) were assessed with tissue Doppler.

In spite of similar non-significant lowering of glycosylated haemoglobin (HbA1C), rosiglitazone, but not glimepiride, significantly improved E’ (p=0.04), reduced malondialdehyde (p=0.028), lowered high-sensitivity C-reactive protein (hsCRP) (p=0.019), and increased adiponectin (p=0.002). For rosiglitazone, multivariate regression analysis revealed malondialdehyde reduction as an independent determinant of treatment-induced improvement in E’.

The rosiglitazone-induced improvements of diastolic function and oxidative stress may be of prognostic relevance in choosing therapy for T2DM patients without overt heart disease.

Keywords

diastolic function oxidative stress rosiglitazone thiazolidinediones tissue Doppler type 2 diabetes

References

1. Ren J Dominguez LJ , Sowers RJ , Davidoff JA. Troglitazone attenuates high-glucose-induced abnormalities in relaxation and intracellular calcium in rat ventricular myocytes. Diabetes 1996;45:1882–25.

2. Zhou YT Grayburn P , Karim A et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci 2000;97:1784–9.

3. Tsuji T Mizushige K , Noma T et al. Pioglitazone improves left ventricular diastolic function and decreases collagen accumulation in prediabetic stage of a type II rat. J Cardiovasc Pharmacol 2001;38:868–74.

4. Erdmann E Dormandy JA , Charbonnel B , Massi-Benedetti M , Moules JK , Skene AM , PROactive investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007;49:1772–80.

5. Dargie HJ Hildebrandt PR , Riegger GAJ et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association functional class I or II heart failure. J Am Coll Cardiol 2007;49:1696–704.

6. Dormandy JA Charbonnel B , Eckland DJ et al. PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macrovascular Events): a randomised controlled trial. Lancet 2005;366:1279–89.

7. Kahn SE Haffner SM , Heise MA et al. ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427–43.

8. Home PD Pocock SJ , Beck-Nielsen H et al. RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes – an interim analysis. N Engl J Med 2007;357:28–38.

9. von Bibra H , Hansen A , Dounis V , Bystedt T , Malmberg K , Rydén L. Augmented metabolic control improves myocardial diastolic function and perfusion in patients with type 2 diabetes mellitus. Heart 2004;90:1483–4.

10.

10. Iribarren C Karter HJ , Go AS et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 2001;103:2668–73.

11.

11. Lautamäki R , Airaksinen KEJ , Seppänen M et al. Insulin improves myocardial blood flow in patients with type 2 diabetes and coronary artery disease. Diabetes 2006;55:511–16.

12.

12. Gaenzer H Neumayr G , Marschang P et al. Effect of insulin therapy on endothelium-dependent dilatation in diabetes mellitus. Am J Cardiol 2002;89:431–4.

13.

13. Wackers FJ Chyun DA , Young LH et al. Detection of Ischemia in Asymptomatic Diabetics (DIAD) Investigators. Resolution of asymptomatic myocardial ischemia in patients with type 2 diabetes mellitus in the DIAD Study. Diabetes Care 2007;30:2892–8

14.

14. Liu JE Palmieri V , Roman MJ et al. The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: The Strong Heart Study. J Am Coll Cardiol 2001;37:1943–9.

15.

15. Celentano A Vaccaro O , Tammaro P et al. Early abnormalities of cardiac function in non-insulin-dependent diabetes mellitus and impaired glucose tolerance. Am J Cardiol 1995;76:1173–6.

16.

16. Haffner SM Stern MP , Hazuda HP , Mitchell BD , Patterson KJ.

Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?

JAMA 1990;263:2893–8.

17.

17. Reaven GM. Why Syndrome X? From Harold Himsworth to the Insulin Resistance Syndrome. Cell Metab 2005;1:9–14.

18.

18. Ceriello A Taboga C , Tonutti L et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation. Circulation 2002;106:1211–24.

19.

19. Young ME McNulty P , Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes. II. Potential mechanisms. Circulation 2002;105:1861–70.

20.

20. Boudina S Abel DE. Diabetic cardiomyopathy revisited. Circulation 2007;115:3213–23.

21.

21. Bella JN Palmieri V , Roman MJ et al. Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle-aged and elderly adults. The Strong Heart Study. Circulation 2002;105:1928–33.

22.

22. von Bibra H , Thrainsdottir IS , Hansen A , Dounis V , Malmberg K , Rydén L. Tissue Doppler imaging for the detection and quantitation of myocardial dysfunction in patients with type 2 diabetes mellitus: A methodological study. Diabetes Vasc Dis Res 2005;2:24–30.

23.

23. Nagueh SF Middleton KJ , Kopelen HA , Zoghbi WA , Quinones AM. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 1997;30:1527–33.

24.

24. Matthews DR Hosker JP , Rudenski AS , Naylor BA , Treacher DR , Turner CR. Homeostasis model assessment: insulin resistance and ß-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–19.

25.

25. Van de Kerkhof J , Schalkwijk CG , Konings CJ et al. Nepsilon-(carboxymethyl)lysine, Nepsilon-(carboxyethyl)lysine and Vascular cell adhesion molecule-1 (VCAM-1) in relation to peritoneal glucose prescription and residual renal function; a study in peritoneal dialysis patients. Nephrol Dial Transplant 2004;19:910–16.

26.

26. Hansen A Johansson BL , Wahren J , von Bibra H. C-peptide exerts beneficial effects on myocardial blood flow and function in patients with type 1 diabetes. Diabetes 2002;51:3077–82.

27.

27. Yu CM Sanderson JE , Marwick TH , Oh KJ. Tissue Doppler Imaging. A new prognosticator for cardiovascular disease. J Am Coll Cardiol 2007;49:1903–14.

28.

28. Kasner M Westermann D , Steendijk P et al. Utility of Doppler echocardiography and tissue Doppler imaging in the estimation of diastolic function in heart failure with normal ejection fraction – a comparative Doppler-conductance catheterization study. Circulation 2007;116:637–47.

29.

29. Paulus WJ Tschöpe C , Rusconi C et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007;28:2539–50.

30.

30. Dounis V Siegmund T , Jensen J , Hansen A , Schumm-Draeger PM , von Bibra H. Global myocardial perfusion and diastolic function are impaired to a similar extent in patients with type 2 diabetes mellitus and in patients with coronary artery disease- evaluation by contrast echocardiography and pulsed tissue Doppler. Diabetologia 2006;49:2729–40.

31.

31. Diamant M Lamb HJ , Groeneveld Y et al. Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol 2003;42:328–35.

32.

32. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54:1615–25.

33.

33. Diamant M Lamb HJ , Smit JWA , de Roos A , Heine RJ. Diabetic cardiomyopathy in uncomplicated type 2 diabetes is associated with the metabolic syndrome and systemic inflammation. Diabetologia 2005;48:1669–70.

34.

34. Houstis N Rosen ED , Lander SE. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006;440:944–8.

35.

35. Barouch LA Harrison RW , Skaf MW et al. Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature 2002;426:337–9.

36.

36. Shah AM. MacCarthy PA. Paracrine and autocrine effects of nitric oxide on myocardial function. Pharmacol Ther 2000;86:49–86.

37.

37. Wang S Jiang JL , Hu CP , Yang DL , Li JY. Relationship between protective effects of rosiglitazone on endothelium and endogenous nitric oxide synthase inhibitor in STZ-induced diabetic rats and cultured endothelial cells. Diabet Metab Res Rev 2007;23:157–64.

38.

38. Huang H Shan J , Pan X-H , Wang H-P , Qian L-B , Xia Q. Carvedilol improved diabetic rat cardiac function depending on antioxidant ability. Diabetes Res Clin Pract 2007;75:7–13.

39.

39. Yue TL Bao W , Gu JL et al. Rosiglitazone treatment in Zucker diabetic fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury. Diabetes 2005;54:554–62.

40.

40. Abdelrahman M Sivarajah A , Thiemermann C. Beneficial effects of PPAR-γ ligands in ischemia-reperfusion injury, inflammation and shock. Cardiovasc Res 2005;65:772–81.

41.

41. Vasan RS Sullivan LM , Roubenoff R et al. Framingham Heart Study. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 2003;107:1486–91.

42.

42. Diamant M Heine JR. Thiazolidinediones in type 2 diabetes: current clinical evidence. Drugs 2003;63:1373–405.

43.

43. Han SH Quon MJ , Kim JA , Koh KK. Adiponectin and cardiovascular disease: response to therapeutic interventions. J Am Coll Cardiol 2007;49:531–8.

44.

44. Shibata R Izumiya Y , Sato K et al. Adiponectin protects against the development of systolic dysfunction following myocardial infarction. J Mol Cell Cardiol 2007;42:1065–74.

45.

45. The DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096–105.

46.

46. St. John Sutton M, Rendell M, Dandona P et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002;25:2058–64.

47.

47. Masoudi FA Inzucchi SE , Wang Y , Havranek EP , Foody JM , Krumholz MH. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005;111:583–90.

48.

48. Hirayama H Sugano M , Abe N , Yonemoch H , Makino N. Troglitazone, an antidiabetic drug, improves left ventricular mass and diastolic function in normotensive diabetic patients. Int J Cardiol 2001;77:75–9.

49.

49. Horio T Suzuki M , Suzuki K , Hiuge A , Yoshimasa Y , Kawano Y. Pioglitazone improves left ventricular diastolic function in patients with essential hypertension. Am J Hypertens 2005;18:949–57.

50.

50. Nissen SE Wolsky K Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457–71.

51.

51. Singh S Loke YK , Furberg DC. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298:1216–18.

52.

52. Bolen S Feldman L , Vassy J et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007;147:428–30.